Literature DB >> 15696189

Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1.

Yoh Zen1, Kenichi Harada, Motoko Sasaki, Tse-Ching Chen, Miin-Fu Chen, Ta-Sen Yeh, Yi-Yin Jan, Shiu-Feng Huang, Yuji Nimura, Yasuni Nakanuma.   

Abstract

Transforming growth factor-beta1 (TGF-beta1) is involved in tumor progression by promoting angiogenesis or suppressing the immune system; yet TGF-beta1 also has a growth-inhibitory effect on epithelial cells including carcinoma cells. Several mechanisms of impaired TGF-beta1 responsiveness of carcinoma cells have been reported. In this study, we examined how TGF-beta1 participates in the development and progression of intrahepatic cholangiocarcinoma (ICC) associated with hepatolithiasis, and how ICC cells escape from growth inhibitory effect of TGF-beta1. A total of 40 cases of hepatolithiasis were studied, including 16 cases of ICC, and in vitro studies were conducted with cultured murine non-neoplastic biliary epithelial cells (MBEC) and three ICC cell lines. Immunohistochemically, TGF-beta1 was expressed in mononuclear cells and mesenchymal cells around the stone-containing bile ducts and invasive ICC, and also in biliary epithelial cells (hyperplastic and precursor lesions, and ICC). TGF-beta type II receptor (TbetaR-II) was constantly expressed on biliary epithelial cells irrespective of biliary lesions. In cell culture studies, TGF-beta1 significantly inhibited proliferation of MBEC via downregulation of cyclin D1, cdk4, and cdk6, while TGF-beta1 did not influence the proliferation of ICC cells. After suppression of cyclin D1 expression in one ICC cell line using cyclin D1 small interfering RNA, TGF-beta1 significantly inhibited the proliferation of ICC cells. In conclusion, high levels of TGF-beta1 around ICC or its precursors may be involved in development and progression of ICC in hepatolithiasis. ICC cells could escape the growth inhibitory effect of TGF-beta1 by overexpression of cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15696189     DOI: 10.1038/labinvest.3700236

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  17 in total

1.  Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

Authors:  Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica
Journal:  Am J Pathol       Date:  2017-03-15       Impact factor: 4.307

2.  Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma.

Authors:  Yasunori Sato; Kenichi Harada; Keita Itatsu; Hiroko Ikeda; Yuko Kakuda; Syuji Shimomura; Xiang Shan Ren; Norihide Yoneda; Motoko Sasaki; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

Review 3.  Genetics of biliary tract cancers and emerging targeted therapies.

Authors:  Aram F Hezel; Vikram Deshpande; Andrew X Zhu
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

4.  Molecular mechanisms of cholangiocarcinoma.

Authors:  Giammarco Fava
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

5.  Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics.

Authors:  Alexandre Dos Santos; Magali Court; Valérie Thiers; Sokhavuth Sar; Catherine Guettier; Didier Samuel; Christian Bréchot; Jérôme Garin; France Demaugre; Christophe D Masselon
Journal:  Mol Cell Proteomics       Date:  2010-05-31       Impact factor: 5.911

6.  Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.

Authors:  Tetsuya Shimizu; Shigeki Yokomuro; Yoshiaki Mizuguchi; Yutaka Kawahigashi; Yasuo Arima; Nobuhiko Taniai; Yasuhiro Mamada; Hiroshi Yoshida; Koho Akimaru; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

7.  Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression.

Authors:  Chiung-Kuei Huang; Arihiro Aihara; Yoshifumi Iwagami; Tunan Yu; Rolf Carlson; Hironori Koga; Miran Kim; Jing Zou; Sarah Casulli; Jack R Wands
Journal:  Cancer Lett       Date:  2016-06-27       Impact factor: 8.679

Review 8.  Genetic and molecular abnormalities in cholangiocarcinogenesis.

Authors:  Victor J Hassid; Frank A Orlando; Ziad T Awad; Dongfeng Tan; Thaer Khoury; Bestoun H Ahmed; Sadir J Alrawi
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

9.  Molecular pathogenesis of cholangiocarcinoma.

Authors:  G Fava; I Lorenzini
Journal:  Int J Hepatol       Date:  2011-07-21

10.  Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma.

Authors:  Sung Ryol Lee; Jae Wook Shin; Hyung Ook Kim; Byung Ho Son; Chang Hak Yoo; Jun Ho Shin
Journal:  Oncol Lett       Date:  2012-11-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.